(Q33555851)

28 July 2017

title

Effect of antacids and ranitidine on the single-dose pharmacokinetics of fosamprenavir (English)

1 reference

28 July 2017

1 reference

1 reference

Susan L Ford

1

1 reference

28 July 2017

Mary B Wire

2

1 reference

28 July 2017

Yu Lou

3

1 reference

28 July 2017

Katherine L Baker

4

1 reference

28 July 2017

Daniel S Stein

5

1 reference

28 July 2017

language of work or name

English

0 references

publication date

1 January 2005

1 reference

Antimicrobial Agents and Chemotherapy

28 July 2017

published in

1 reference

28 July 2017

volume

49

1 reference

28 July 2017

issue

1

1 reference

28 July 2017

page(s)

467-469

1 reference

Preclinical pharmacology and pharmacokinetics of GW433908, a water-soluble prodrug of the human immunodeficiency virus protease inhibitor amprenavir

28 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=538899

Six-week randomized controlled trial to compare the tolerabilities, pharmacokinetics, and antiviral activities of GW433908 and amprenavir in human immunodeficiency virus type 1-infected patients

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=538899

Pharmacokinetic and pharmacodynamic study of the human immunodeficiency virus protease inhibitor amprenavir after multiple oral dosing

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=538899

Pharmacologic characteristics of indinavir, didanosine, and stavudine in human immunodeficiency virus-infected children receiving combination therapy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=538899

Indinavir concentrations and antiviral effect

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=538899

Effervescent and standard formulations of ranitidine--a comparison of their pharmacokinetics and pharmacology.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=538899

Ordered accumulation of mutations in HIV protease confers resistance to ritonavir

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=538899

Comparative studies of two-times-daily versus three-times-daily indinavir in combination with zidovudine and lamivudine.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=538899

A 24-week open-label phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir).

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=538899

Toxicity, efficacy, plasma drug concentrations and protease mutations in patients with advanced HIV infection treated with ritonavir plus saquinavir. Swiss HIV Cohort Study

31 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/15616339

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1128/AAC.49.1.467-469.2005

1 reference

28 July 2017

1 reference

28 July 2017

1 reference